 Mepolizumab is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of severe asthma in patients aged 6 years or older and with an eosinophilic phenotype in combination with other medicines used to treat asthma.In Europe it is approved as an add-on treatment for severe refractory eosinophilic asthma in adult patients.In studies, mepolizumab cut the necessity for hospitalisation due to asthma exacerbations in half, as compared to placebo.